Search for:

In brief

With a Report published on 21 April 2021, the Italian Medicines Agency (AIFA) made available the preliminary data relating to the Monitoring of the National and Regional Pharmaceutical Expenditure for the year 2020.


According to the Report, during that period the total national expenditure, including both the pharmaceutical expenditure for direct purchases and the territorial expenditure, amounted to EUR 18,890.3 million, showing an increase of approximately EUR 200 million compared to the previous year and a departure from the total resources of approximately EUR 1,134.2 million.

Moreover, data, which are in line with the growth trend observed over recent years, show that the pharmaceutical expenditure for direct purchases exceeded the annual expenditure ceiling (equal to EUR 2,700 million), whilst territorial expenditure stayed below the ceiling of EUR 1,565 million.

Author

Roberto Cursano is a counsel in Baker Mckenzie since 2007 in Rome, Italy office. His practice focus more in pharmaceutical and healthcare law matters and compliance, and assists in tender procedures, the negotiation of public contracts and litigation before administrative courts.

Author

Riccardo Ovidi is an associate in Baker McKenzie's Rome office.

Write A Comment